Subviral particle as vaccine and vaccine platform

Recombinant subvirual particles retain similar antigenic features of their authentic viral capsids and thus have been applied as nonreplicating subunit vaccines against viral infection and illness. Additionally, the self-assembled, polyvalent subviral particles are excellent platforms to display for...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Ming, Jiang, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072748/
https://www.ncbi.nlm.nih.gov/pubmed/24662314
http://dx.doi.org/10.1016/j.coviro.2014.02.009
_version_ 1782323015638319104
author Tan, Ming
Jiang, Xi
author_facet Tan, Ming
Jiang, Xi
author_sort Tan, Ming
collection PubMed
description Recombinant subvirual particles retain similar antigenic features of their authentic viral capsids and thus have been applied as nonreplicating subunit vaccines against viral infection and illness. Additionally, the self-assembled, polyvalent subviral particles are excellent platforms to display foreign antigens for immune enhancement for vaccine development. These subviral particle-based vaccines are noninfectious and thus safer than the conventional live attenuated and inactivated vaccines. While several VLP vaccines are available in the markets, numerous others, including dual vaccines against more than one pathogen, are under clinical or preclinical development. This article provides an update of these efforts.
format Online
Article
Text
id pubmed-4072748
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-40727482015-06-01 Subviral particle as vaccine and vaccine platform Tan, Ming Jiang, Xi Curr Opin Virol Article Recombinant subvirual particles retain similar antigenic features of their authentic viral capsids and thus have been applied as nonreplicating subunit vaccines against viral infection and illness. Additionally, the self-assembled, polyvalent subviral particles are excellent platforms to display foreign antigens for immune enhancement for vaccine development. These subviral particle-based vaccines are noninfectious and thus safer than the conventional live attenuated and inactivated vaccines. While several VLP vaccines are available in the markets, numerous others, including dual vaccines against more than one pathogen, are under clinical or preclinical development. This article provides an update of these efforts. Elsevier B.V. 2014-06 2014-03-21 /pmc/articles/PMC4072748/ /pubmed/24662314 http://dx.doi.org/10.1016/j.coviro.2014.02.009 Text en Copyright © 2014 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Tan, Ming
Jiang, Xi
Subviral particle as vaccine and vaccine platform
title Subviral particle as vaccine and vaccine platform
title_full Subviral particle as vaccine and vaccine platform
title_fullStr Subviral particle as vaccine and vaccine platform
title_full_unstemmed Subviral particle as vaccine and vaccine platform
title_short Subviral particle as vaccine and vaccine platform
title_sort subviral particle as vaccine and vaccine platform
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072748/
https://www.ncbi.nlm.nih.gov/pubmed/24662314
http://dx.doi.org/10.1016/j.coviro.2014.02.009
work_keys_str_mv AT tanming subviralparticleasvaccineandvaccineplatform
AT jiangxi subviralparticleasvaccineandvaccineplatform

Ejemplares similares